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N E U R O - O N C O L O G Y
Abstracts
IMMUNOLOGY RESEARCH
IR-01. CYTOMEGALOVIRUS SUBVERTS THE MONOCYTE
LINEAGE TO BECOME GLIOMA PROPAGATING
Kristine Dziurzynski1, Jun Wei1, Wei Qiao1, Mustafa A. Hatiboglu1,
Ling-Yuan Kong1, Adam Wu2, Yongtao Wang1, Daniel P. Cahill1, Nicholas
B. Levine1, Sujit S. Prabhu1, Ganesh Rao1, Raymond Sawaya1, and Amy
B. Heimberger1; 1The University of Texas MD Anderson Cancer Center,
Houston, TX; 2Royal University Hospital, Saskatoon, SK, Canada
We have identified a mechanism by which cytomegalovirus (CMV)
interleukin-10 (IL-10) is utilized by glioblastoma multiforme (GBM) to
maintain the immunosuppressive microenvironment. CMV has been ubiqui-
tously detected within high-grade gliomas, but its role has not been fully eli-
cited. GBMs harvested ex vivo were analyzed by flow cytometry to determine
CMV antigen expression. Distinct expressing subsets of cells, such as the
myeloid lineage and CD133+ cells, were identified. CMV antigens US28,
pp65, IE1, and gB were also present within four individual and fully charac-
terized human GBM-derived glioma cancer stem cell (gCSC) populations as
ascertained by flow cytometry. These gCSCs produce CMV IL-10 in a range
from 5.62 to 111.11 pg/mL/106cells/day. When human CD14+ mono-
cytes, precursor cells to macrophages/microglia, were exposed to
gCSC-conditioned medium or recombinant CMV IL-10, there was a
marked increase in the expression of immune-suppressive factors such as
B7-H1, p-STAT3, VEGF, and TGF-beta. Concurrently, anti-tumor and
pro-immune MHC II and CD86 were down-regulated and the expression
pattern of immune markers was similar to the phenotype of
glioma-associated macrophages/microglia. Exposure of CD14+ cells to
CMV IL-10 induced the up-regulation of IE1, a marker of transcriptional
activity of CMV. Chemotaxis assays revealed that the supernatant from
CD14+ cells exposed to CMV IL-10 was able to induce the migration of
gCSCs compared with the supernatant from CD14+ cells cultured in
medium alone. This result indicates that CMV subverts GBM-associated
macrophages/microglia to support the immune-suppressive microenviron-
ment by shifting their phenotype to the immune-suppressive M2. The shift
is subsequent to activation of the STAT3 pathway, resulting in the propa-
gation of glioma angiogenesis via an increase in VEGF and by increasing
glioma invasion. Therapeutic strategies involving immune-mediated cyto-
toxic responses now include strategies to reverse tumor-mediated immune
suppression. This study suggests that including CMV as a target could
enhance the effectiveness of immunotherapy.
IR-02. IMMUNE-MODULATORY PROPERTIES
OF GLIOBLASTOMA MULTIFORME EXOSOMES
Jeroen de Vrij1, Kitty M.C. Kwappenberg2, Sybren L.N. Maas3, Anne Kleijn1,
Martine L. Lamfers1, Clemens M.F. Dirven1, Marco W. Schilham2, and
Marike L.D. Broekman3; 1Erasmus Medical Center, Rotterdam, the
Netherlands; 2Leiden University Medical Center, Leiden, the Netherlands;
3University Medical Center Utrecht, Utrecht, the Netherlands
The cellular immune response in patients with glioblastoma multiforme
(GBM) displays abnormalities, and the aggressive nature of these tumors
might be related to their capacity to evade the anti-tumoral response.
Because most of the cells involved in the cellular response are not exposed
to the tumor, it has long been thought that tumors secrete factors that
modify the immune system. We hypothesized that exosomes are (at least
some of) these secreted factors. Exosomes are microvesicles 50-100 nan-
ometers in size that are derived from the endosomal pathway and, upon
their release into the extracellular milieu, have been shown to be capable
of modulating their microenvironment via the transfer of (micro)RNAs
and proteins. GBM tumor-derived exosomes (TEXs) have been found in
the serum of patients. It was recently shown in cell culture models that
GBM TEXs can stimulate angiogenesis and cell proliferation, suggesting
an important role for TEXs in tumor biology. To assess the effects of
GBM exosomes on the cellular immune response, we isolated exosomes
from the supernatant of GBM cell lines, GBM primary cell cultures, and
serum of GBM patients. Peripheral blood mononuclear cells from healthy
donors were exposed to the exosomes in vitro and were subsequently
analyzed by flow cytometry. We observed higher CD14 expression and
lower HLA-DR expression on monocytes after 3 days of exposure of the per-
ipheral blood mononuclear cells to GBM exosomes than on monocytes
exposed to medium alone. The effect on monocytes was also observed
with a purified monocyte population, indicating a direct effect. These
results correspond to the changes in the phenotype of monocytes in periph-
eral blood of GBM patients and suggest an important immunomodulatory
role for brain tumor exosomes.
IR-03. INTENSE HUMAN CYTOMEGALOVIRUS (HCMV)
IMMUNE RESPONSE IN GLIOBLASTOMA PATIENTS: A
PROGNOSTIC FACTOR FOR SURVIVAL
Adelaida Garcia-Velasco1, Sonia del Barco2, Rafael Alvarez1, Rafael Fuentes2,
Jordi Marruecos2, Ovidio Hernando1, Carmen Rubio1, Javier Menendez2,
Joan Brunet2, and Manuel Hidalgo1; 1Clara Campal Oncologic Center,
Universitary Hospital Madrid Sanchinarro, Madrid, Spain; 2Institut Catalá
d’Oncologia, Hospital Dr. Josep Trueta, Girona, Spain
INTRODUCTION: HCMV is a ubiquitous human herpesvirus found in
nearly all humans worldwide, with persistent infection occurring in over
70% of adults. The virus has been implicated in the development of
several human malignancies owing to the oncomodulatory effects of
HCMV infection. There is growing scientific evidence about an association
between HCMV and malignant gliomas. To study the prognostic value of
the anti-HCMV immune response, we prospectively assessed the levels of
serum HCMV immunoglobulins M and G (IgM and IgG) in newly diagnosed
glioblastoma patients and correlated the results with the clinical course.
METHODS: We analyzed serum from 32 glioblastoma patients treated
with standard chemoradiotherapy at our institution between November
2008 and October 2010. CMV serologies were obtained by chemiluminis-
cent quantitative analyses. HCMV IgM .0.5 UA/ml was considered diag-
nostic for acute HCMV infection, and HCMV IgG .16 UA/ml was
regarded as positive for latent infection. Intense HCMV IgG immune
response was defined as HCMV IgG .100 UA/ml. All clinical and patho-
logical data were recorded in a database system using the SPSS version
13.0 statistics package. RESULTS: After a median follow-up of 18.2
months, 24 patients (75%) have died. HCMV IgG was positive for latent
infection in 23 patients (72%), 10 of whom had intense response (31%).
Two patients had an acute HCMV reactivation with positive values for
IgM. In univariate analysis, HCMV IgG .100 UAI/ml demonstrated a
strong significant association with a longer overall survival (p ¼ 0.0087).
Positive HCMV IgG was found to be marginally associated with survival
(p ¼ 0.07). In multivariate analysis, HCMV IgG .100 UAI/ml retained
statistically significant as a prognostic factor for longer survival (hazard
ratio, 0.18; 95% CI 0.04-0.81; p ¼ 0.02). CONCLUSION: Intense HCMV
IgG immune response is significantly associated with longer overall survival
in our series. Larger studies are required to validate HCMV IgG as a
prognostic factor for survival in glioblastoma patients.
IR-04. TUMOUR-INFILTRATING T-CELL SUBPOPULATIONS
IN GLIOBLASTOMAS
Tae-Young Jung, Young-Hee Kim, Shin Jung, Woo-Youl Jang,
Kyung-Sub Moon, In-Young Kim, Min-Cheol Lee, and Je-Jung Lee;
Chonnam National University Hwasun Hospital, Chonnam, Republic
of Korea
This study was designed to determine the incidence and prognostic value
of various populations of tumour-infiltrating T cells in glioblastomas. We
also evaluated the difference in T-cell populations after conventional treat-
ment. Sixty-seven patients with glioblastomas underwent surgery between
2003 and April 2009. Immunohistochemical staining was performed for
CD3, CD4, CD8, and FoxP3, and the average number and percentage of
positive cells were calculated. From eight patients, the average number of
subpopulations was compared between the specimens obtained during the
first and second operations. Age, gender, Karnofsky performance status,
RTOG-RPA class, extent of removal, treatment modality, MGMT methyl-
ation status, and immunopositivity for CD3, CD4, CD8, and FoxP3 were
analyzed as prognostic factors. There was an average of 12.8+1.8 CD3+
T cells, 1.5+0.5 CD4+ T cells, 6.8+1.3 CD8+ T cells, and 0.6+0.2
FoxP3+ T cells. The percentage of positive T-cell subpopulations was
89.6%, 22.4%, 77.6%, and 34.3% for CD3, CD4, CD8, and FoxP3,
respectively. Among the eight patients there was no difference in the sub-
populations between the first and second operations. The median
progression-free survival was 7.0 months (95% CI, 5.2-8.9 months) and
the overall survival was 14.8 months (95% CI, 11-18.7 months).
Univariate analysis showed a statistically significant difference in
progression-free survival for CD8 (p ¼ 0.02) and in overall survival for
Neuro-Oncology 13:iii30–iii33, 2011.
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RTOG-RPA class (p ¼ 0.003), extent of removal (p ¼ 0.01), and MGMT
promoter methylation status (p ¼ 0.005). On the basis of the multivariate
analysis results, RTOG-RPA class was significantly associated with longer
overall survival. The intra-tumoural immune response occurred frequently
in glioblastomas and there was a consistent response, even after conventional
treatment. There was a statistically significant difference in progression-free
survival for CD8 in immunologically privileged central nervous systems.
IR-05. INTERLEUKIN-4 RECEPTOR ALPHA CHAIN
(IL-4R-ALPHA) PROMOTES THE IMMUNOSUPPRESSIVE
ACTIVITY OF GLIOMA-INFILTRATING MONOCYTES
Gary Kohanbash1, Kayla McKaveney2, Masashi Sakaki1, Arlan Mintz1,
John Ohlfest3, Melissa Bondy4, Mitsugu Fujita5, and Hideho Okada1;
1University of Pittsburgh, Pittsburgh, PA; 2University of
Wisconsin-Madison, Madison, WI; 3University of Minnesota, Minneapolis,
MN; 4The University of Texas MD Anderson Cancer Center, Houston, TX;
5Aichi Cancer Center, Nagoya, Japan
IL-4R-alpha is expressed on immunosuppressive cells of monocyte lineage
and mediates their production of transforming growth factor (TGF)-beta in
response to interleukin-13. We thus hypothesized that IL-4R-alpha
expression on monocytes plays a significant role in glioma development.
Analyses of human glioma-infiltrating leukocytes revealed that
glioma-infiltrating monocytes, but not peripheral blood CD14+ monocytes,
express high levels of IL-4R-alpha, suggesting the unique up-regulation of
IL-4R-alpha in the glioma microenvironment. We next sought to address
the functional significance of IL-4R-alpha in a murine de novo glioma
model. We induced gliomas in BALB/c-background mice by intracerebro-
ventricular transfection of oncogenes using the Sleeping Beauty transposon
system. Il4ra2/- mice exhibited significantly prolonged survival compared
with wild-type (WT) mice. Consistently, gliomas induced in WT mice were
infiltrated with higher numbers of CD11b+Gr1+ monocytes than were
gliomas induced in Il4ra2/-mice. We subsequently isolated glioma-
infiltrating CD11b+Gr1+monocytes to address their functions. RT-PCR
and ELISA revealed that the monocytes derived from WT mice expressed
significantly higher levels of TGF-beta. Additionally, depletion of these
cells using anti-Gr1 antibody in mice significantly prolonged survival
after tumor challenge. Analysis of in vitro cultured bone marrow cells
demonstrated that compared with cells derived from WT mice,
Il4ra2/-mouse-derived cells contained lower numbers of CD11b+Gr1+
monocytes with lower arginase and TGF-beta expression as well as a
decreased ability to suppress T-cells in vivo and in vitro. Because type-1
skewed T-cells in Il4ra2/- animals could have contributed to the observed
better survival compared with WT mice, we next depleted CD4+ and
CD8+ T-cells by using antibodies. Although T-cell depletion shortened the
overall survival of WT and Il4ra2/- mice, T-cell-depleted Il4ra2/- mice still
exhibited enhanced survival over T-cell-depleted WT mice. These data
suggest that IL-4R-alpha expression on glioma-infiltrating monocytes
promotes the immunosuppressive microenvironment of gliomas through a
variety of mechanisms, including TGF-beta production and T-cell inhibition,
thereby facilitating glioma development.
IR-06. IMMUNOLOGICAL SOIL AND PREVENTION
OF BREAST CANCER BRAIN METASTASIS
Yan Liu, Masasuke Ohno, and Hideho Okada; University of Pittsburgh
Cancer Institute, Pittsburgh, PA
As therapies for systemic cancer improve and patients survive longer, the
risk of cerebral metastases increases. Therefore, the cerebral metastasis of
cancers is a major obstacle that must be overcome before cancers can be
cured by any means. In our recent data, mice bearing 4T1 breast cancers
in the primary site (mammary pad) showed accumulations of myeloid-
derived suppressor cells (MDSCs) in the brain before their brains demon-
strated any presence of metastatic tumor cells. These observations were
accompanied by marked up-regulation of the inflammatory chemokines
S100A8, S100A9, and serum amyloid A 3 (SAA3) in the pre-metastatic
brains. Elevated levels of the cytokines tumor necrosis factor alpha and vas-
cular endothelial growth factor, which could induce MDSCs, were detected
in the sera of 4T1-bearing mice. Chemokine CCL2 was also up-regulated in
the pre-metastatic brain of 4T1-bearing mice, and anti-CCL2 treatment
reduced MDSC infiltration. The cyclooxygenase-2 inhibitor celecoxib
reduced MDSC infiltration as well as S100A8, S100A9, and SAA3
expression in the pre-metastatic brains of 4T1-bearing mice. On the other
hand, neither MDSC accumulation nor up-regulation of S100A8, S100A9,
or SAA3 was detected in the brains of mice bearing JC breast cancer cells,
which are not metastatic. Our results suggest that tumor cells with high
metastatic activity in their primary site induce immunosuppressive
conditions in the distant target organs, such as brain, and thereby promote
metastasis. Anti-CCL2 and celecoxib treatments might be used to prevent
the formation of pre-metastatic immunological soil. Further understanding
of the mechanisms underlying the immunological soil will allow us to
develop effective strategies to prevent cerebral metastasis of breast cancer.
IR-07. THE RCAS/TV-A MODEL OF MURINE GLIOMA
REPRODUCES IMMUNOSUPPRESSION PRODUCED
BY MYELOID-DERIVED SUPPRESSOR CELLS IN HUMANS
WITH GBM
Baisakhi Raychaudhuri and Michael A. Vogelbaum; Cleveland Clinic,
Cleveland, OH
Myeloid-derived suppressor cells (MDSCs) are a population of bone
marrow-derived cells with potent immunosuppressive properties. We pre-
viously showed (Neurooncology, 2011) that MDSCs are found at elevated
levels in the circulation of patients with glioblastoma multiforme (GBM)
and that they produce reversible T-cell dysfunction. We now show that
MDSCs are present in GBM tumors and that the mouse model overexpressing
platelet-derived growth factor subunit B in Nestin-tva/ink4a- arf/KO repro-
duces our observations with patients. We collected tumor tissue and blood
from consented patients (n ¼ 3) with newly diagnosed GBM. Peripheral
blood mononuclear cells were isolated, and MDSC subsets were detected by
fluorescence-activated cell sorting analysis. From the murine glioma model
(n ¼ 18 mice) we harvested glioma tumors, normal brain tissue, and hemato-
logic tissues. Cells were dissociated, stained, and subjected to similar analysis.
MDSCs were present in both human and murine gliomas. In murine tumors
there were more monocytic MDSCs (Gr1low, .5%) than neutrophilic
MDSCs (Gr1high, .3%), and both were present at much higher levels in
the tumors than in normal brain tissue (p , 0.016). MDSCs were also
higher in the circulation of mice with gliomas than of control mice, but
there the Gr1high subset predominated. GBM patients also had MDSCs
present in tumor tissue (7.0+3.1%). Subclassification of the MDSCs in the
human samples indicated that lineage-negative MDSCs (CD15-CD14-
CD33 + HLA-DR-) were more prevalent than MDSCs with a neutrophilic
subtype (CD15 + CD14-CD33 + HLA-DR-). We also found that the pro-
liferation and intracellular interferon-gamma level of splenocytes isolated
from normal mice were decreased in the presence of Gr1+ MDSC cells
from murine gliomas, indicating that this model reproduces the
MDSC-induced immunosuppression seen in our GBM patients. We showed
that MDSCs are present in both human and mouse glioma tumors and that
the cells suppress T-cell function. Neutrophilic MDSCs predominate in the
circulation of both species, whereas in the tumors the monocytic MDSCs
dominate in mice and the linage-negative subset dominates in humans.
IR-08. GLIOBLASTOMA-DERIVED EXOSOMES CONTRIBUTE
TO TUMOR IMMUNE EVASION
Keith Z. Sabin1, Danny Lebert2, Vanessa Thibado2, Richard Rovin3,
John Lawrence2, and Robert Winn1; 1Northern Michigan University,
Marquette, MI; 2Upper Michigan Brain Tumor Center, Marquette, MI;
3Marquette General Hospital, Marquette, MI
Glioblastoma multiforme (GBM) is the most frequent and lethal primary
brain tumor in adults. Despite intense biomedical research, the median sur-
vival after diagnosis is 15 months. One factor contributing to this poor prog-
nosis is the immune protection afforded by the tumor microenvironment.
Tumors have a diverse repertoire of immune-evasive techniques. One
method of evasion not well explored is the release of tumor-derived exo-
somes. Exosomes are tiny membrane-bound vesicles of endocytic origin
that contain viable mRNA and functional proteins that can affect the physi-
ology of recipient cells. Exosome release has been reported for numerous
cancer types, including GBM. Exosomes from colon cancer have been
shown to carry Fas ligand (FasL) and to induce apoptosis of activated T
cells. The aim of this study was to elucidate whether the same
immune-evasive technique is used in GBM. GBM exosomes were isolated
from the serum-free culture medium of U87 MG and U138 MG cells by
using differential ultracentrifugation and were then resuspended in
phosphate-buffered saline. The protein concentration of the resulting
exosome pellet was determined, and subsequent exosome treatments were
based on protein concentration. A3T T cells were plated at a concentration
of 10,000 cells per well in 96-well plates and were treated with quantified
exosome fractions or with recombinant FasL, and T cell proliferation was
determined. Our data demonstrated that tumor-derived exosomes signifi-
cantly inhibited the proliferation of T cells and that the cellular inhibition
resulting from the exosomes was comparable to that seen with the recombi-
nant FasL. These results suggest that targeting FasL in GBM could greatly
decrease the amount of immune suppression that occurs at the tumor site.
Abstracts













IR-09. CHARACTERIZATION OF THE IMMUNE RESPONSE
TO ONCOLYTIC ADENOVIRUS THERAPY FOR MALIGNANT
GLIOMA
Anne Kleijn1, Jenneke Kloezeman1, Elike Treffers-Westerlaken1, Giulia Fulci2,
Sieger Leenstra1, Clemens Dirven1, Reno Debets1, and Martine Lamfers1;
1Erasmus Medical Center, Rotterdam, the Netherlands; 2Massachusetts
General Hospital, Harvard Medical School, Boston, MA
The oncolytic adenovirus Delta-24-RGD has demonstrated highly effec-
tive anti-tumor efficacy in various intracranial xenograft models for glioblas-
toma. However, the species specificity of human adenovirus has restricted
preclinical studies to immunocompromised animals. As a result, the role of
the immune system has not been clearly delineated and may be greatly under-
estimated in this type of therapy. Therefore, we set up a syngeneic immune-
competent intracranial model with murine glioma cells found to be
semi-permissive to human adenovirus replication and investigated both the
innate and adaptive immune response to Delta-24-RGD treatment.
C57BL/6 mice were injected stereotactically with GL261 cells and treated
five days later with AdD24RGD or phosphate-buffered serum. At different
early and late time points post-treatment, brain, blood and spleen samples
were collected. Splenocytes were co-cultured with Delta-24-RGD or
GL261 cells and assessed for interferon (IFN)-gamma production. Brain sec-
tions were immunohistochemically stained for various immune cells. Serum
samples were tested for the presence of neutralizing antibodies. A rapid
influx of CD45+ leukocytes and F4/80+ macrophages was detected
within 24 hours after virus treatment. Splenocytes from virus-treated
animals co-cultured with Delta24-RGD produced high levels of
IFN-gamma. Interestingly, splenocytes from virus-treated mice also pro-
duced IFN-gamma when co-cultured with GL261 cells. Splenocytes from
phosphate-buffered serum-treated mice did not respond to virus or to
GL261 cells. High-level neutralizing antibodies were detected in the sera
of mice starting 96 hours post-treatment. In conclusion, the GL261 murine
glioma model offers a system to gain insight into the role of the innate and
adaptive immune response to oncolytic adenovirus treatment in the brain.
We demonstrated that splenocytes from Delta-24-RGD-treated mice recog-
nized both virus and tumor antigens. We also demonstrated that a
humoral response is attempting to neutralize the activity of the virus.
Future experiments will be performed to gain more insight into this response
and to develop strategies to enhance the anti-tumor immune response.
IR-10. STEREOTACTIC RADIOSURGERY COMBINED WITH
DOUBLE IMMUNOTHERAPY WITH ANTI-CTLA-4 AND
ANTI-4-1BB YIELDS LONG-TERM SURVIVAL AND
PROTECTIVE ANTITUMOR RESPONSE IN A MOUSE
ORTHOTOPIC GLIOBLASTOMA MODEL
Zineb Belcaid, Jillian A. Phallen, Jing Zeng, Alfred P. See, Emilia Albesiano,
Nicholas M. Durham, Betty Tyler, Henry Brem, Drew M. Pardoll,
Charles Drake, and Michael Lim; Johns Hopkins University, Baltimore, MD
Despite the best available therapies for glioblastoma multiforme, progno-
sis for patients remains poor. We tested an immunotherapeutic approach
using two monoclonal antibodies in combination with stereotactic radiosur-
gery: anti-CTLA-4 blockade and anti-4-1BB agonist. CTLA-4 downregulates
pathways of T-cell activation, while signaling through 4-1BB triggers T-cell
expansion. Evidence that radiation alters the tumor microenvironment to
enhance recruitment of antitumor T cells supports the strategy to unite radio-
therapy and immunotherapy. To establish orthotopic tumors, GL261 glioma
cells transfected with luciferase were intracranially implanted into C57/BL6
mice. On day 7 after implantation, mice were stratified into four treatment
groups using bioluminescent imaging: (1) isotype controls, (2) stereotactic
radiation, (3) anti-4-1BB and anti-CTLA-4 antibodies, and (4) stereotactic
radiation with anti-4-1BB and anti-CTLA-4 antibodies. Stereotactic radi-
ation was delivered on day 10 after implantation under computed tomo-
graphic guidance on a small-animal irradiator using a 3-mm beam set to
10 Gy. We administered anti-4-1BB on days 11, 14, and 17 and
anti-CTLA-4 on days 11, 17, and 23. Overall survival was quantified.
Protective antitumor memory response in the long-term survivors was
assessed using subcutaneous tumor re-challenge compared to a group of
naı̈ve animals. The median survival time was 18 days for control animals,
19 days in the anti-4-1BB and anti-CTLA-4 arm, and 23 days in the stereo-
tactic radiation arm. As of day 100 post-implantation, 50% of mice in the
treatment arm combining stereotactic radiation with anti-4-1BB and
anti-CTLA-4 antibodies are classified as long-term survivors; thus, the
median survival for this treatment group has not been reached. After
tumor re-challenge, all naı̈ve animals had palpable tumors by day 17,
whereas the long-term survivors had no sign of tumor growth by day 50.
Our study shows that double immunotherapy using anti-4-1BB agonist
and anti-CTLA-4 blockade combined with stereotactic radiosurgery results
in long-term survival with development of a protective memory response.
IR-11. MODULATION OF NEUTROPHIL ACTIVATION
BY TUMOR AND TUMOR-ASSOCIATED NECROSIS
IN GLIOBLASTOMA
Trisha R. Sippel, Jason White, Rae Russel, and Allen Waziri; University of
Colorado Anschutz Medical Campus, Aurora, CO
We recently identified an immunosuppressive mechanism in GBM patients
through which neutrophilic degranulation and release of arginase I resulted
in reversible T-cell dysfunction. We noted isolated instances of increased
neutrophilic infiltration of GBM, but the mechanism through which signifi-
cant numbers of activated neutrophils persist within the peripheral circula-
tion of these patients remains unclear. We hypothesized that
tumor-associated factors are responsible for the activation and subsequent
alteration of surface-binding proteins of neutrophils within the tumor micro-
vasculature. To initially explore this hypothesis, normal donor neutrophils
were incubated with tumor-conditioned medium or necrotic material.
Induction of degranulation was measured via flow-cytometric quantification
of surface markers associated with neutrophilic activation. Following incu-
bation with conditioned medium or necrotic material, increased surface
expression was observed for both CD11b (1.6- and 1.5-fold, respectively)
and CD66 (1.7- and 1.4-fold, respectively), confirming tumor-specific induc-
tion. In further exploration of baseline characteristics of circulating neutro-
phils in GBM patients, resting and degranulated populations were purified
from peripheral blood using a dual-density Histopaque gradient. Baseline
expression patterns of CD11b and CD66 on resting neutrophils were equiv-
alent to those of normal donor neutrophils, and functional analysis using
fMLP-induced activation confirmed parallel degranulation responses. As
expected, degranulated neutrophils from GBM patients demonstrated elev-
ated expression of CD66, consistent with activation. However, degranulated
neutrophils expressed paradoxically low levels of CD11b and high levels of
L-selectin (0.6- and 1.3-fold, respectively, compared with normal cells).
Because CD11b is required for strong intravascular adhesion and
L-selectin is normally shed prior to neutrophil transmigration, these data
suggest that peritumoral activation may result in degranulation without
effective intratumoral infiltration. These results provide a preliminary expla-
nation for the prevalence of degranulated neutrophils within the peripheral
circulation of GBM patients. In addition, we propose that factors present
within the tumor microvasculature induce important changes in the func-
tional binding characteristics of these cells.
IR-12. ELK-1 REGULATES INTERFERON-ALPHA-8 EXPRESSION
VIA A POLYMORPHIC REGION IN INTERFERON-ALPHA-8
PROMOTER ASSOCIATED WITH THE PROGNOSIS OF GLIOMA
PATIENTS
Gary Kohanbash1, Eiichi Ishikawa2, Mitsugu Fujita3, Masasuke Ohno1,
Yan Liu1, Masashi Sakaki1, Maki Ikeura1, Michael Scheurer4,
Melissa Bondy5, and Hideho Okada1; 1University of Pittsburgh, Pittsburgh,
PA; 2University of Tsukuba, Ibaraki, Japan; 3Aichi Cancer Center, Nagoya,
Japan; 4Baylor College of Medicine and The University of Texas MD
Anderson Cancer Center, Houston, TX; 5University of Texas, Houston, TX
Several studies have demonstrated a significant immunological impact of
single nucleotide polymorphisms (SNPs) in innate immune response-related
genes, such as Toll-like receptors 3 and 4 (TLR3 and TLR4). We recently
reported that among patients with WHO grade 2 and 3 gliomas, those
with the AA genotype of the rs12553612 SNP in the interferon-alpha-8
(IFNA8) promoter region had better overall survival than did those with
the AC genotype. On the basis of these observations we hypothesized that
compared with the C allele, the A allele in the IFNA8 promoter allows for
enhanced transcription factor binding and expression levels of IFNA8.
Analyses of THP-1 cells transfected with a luciferase gene downstream of
a short sequence containing the SNP in the IFNA8 promoter demonstrated
that the A allele results in enhanced promoter activity. In silico analysis
suggested c-Krox and ELK-1 as likely transcription factors that bind to the
IFNA8 polymorphic region. Co-transfection of plasmids encoding the
c-Krox or ELK-1 and the luciferase constructs revealed that ELK-1 negatively
regulated promoter activity with the A allele but not the C allele, whereas
c-Krox did not affect activity regardless of the allele. Transfection of
ELK-1 small interfering RNA into THP-1 cells consistently resulted in
increased promoter activity. To further identify factors that contribute to
enhanced A allele promoter activity, we assessed the effects of drugs that
inhibit intracellular signaling pathways: PD98059 (which inhibits MEK/
ERK), SB203580 (p38), and PPase-2B (small molecules). Use of any of one
of the inhibitors resulted in decreased activity of the A allele promoter, indi-
cating that multiple proteins or a protein common to multiple pathways is
involved. Taken together, our data demonstrate that the A allele in the
IFNA8 promoter, which is associated with better survival for glioma
patients, allows for enhanced promoter activity that in turn is negatively
regulated by ELK-1 and further regulated by multiple signaling pathways.
Abstracts













IR-13. COMPREHENSIVE CHARACTERIZATION OF HUMAN
CYTOMEGALOVIRUS INFECTION IN THE LONG-TERM
INFECTED T98G CELL MODEL
Han Qing Yi1, Ying Ling Duan1, Cui Qing Yang1, Keun Seok Seo2,
Gregory Bohach2, Elizabeth Fortunato2, and Min Hua Luo1; 1Wuhan
Institute of Virology, Chinese Academy of Sciences, Wuhan, China;
2University of Idaho, Moscow, ID
HCMV is the leading viral cause of birth defects, affecting primarily the
central nervous system. It is also strongly associated with glioma in adults
and plays a role via oncomodulation. Previously we created an
HCMV-infected T98G cell line long-term infection model (J Virol 2007).
We investigated HCMV infection by culturing infected cells longer term
without passaging and viral genome persistence in infected cells with con-
tinuous passaging. HCMV Ag+ cells formed clusters during long-term
culture without passaging. Maintenance of the viral genome in T98G
cells was determined by PCR, nested PCR, and FISH, and viral genome
copy number was analyzed by qPCR. PCR and nested PCR results
showed that viral genome lasted to passage 7 (24 days post-infection) and
to at least passage 13 (42 days post-infection), respectively; there was a
high copy number of the viral genome at earlier passages, and the copy
number was maintained around 400 from passages 10 through 13. To
confirm that the viral genome was retained in Ag- (GFP-IE22) cells,
GFP-fused virus (WT-J-eGFP) was used for infection, purified Ag- cells
were collected and cultured with continuous passaging, and viral
genomes were detected by FISH. All cells had about 30 spots of HCMV
genome in the nuclei. To investigate the HCMV infection feature in
T98G cells, cells were transfected with p53 (host factor) and the IE1
protein-positive rate increased one-fold; for viral factors, pp71 mutant
virus (T223A) and clinical isolates (TR and Tolledo) were used to infect
cells. Cells with the mutant virus infection had a higher IE1
protein-expressing rate; clinical isolates went into latency directly or
faster. Thus, HCMV infection in T98G cells without the disturbance of pas-
saging forms Ag+ clusters, indicating that infection in the brain without
interference may become worse. High copy number, HCMV genome per-
sistence, and cellular and viral factors affected HCMV gene expression
but could not change the infection, indicate a promising latent infection
model that would be useful in glioma oncomodulation studies.
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